Retrieve available abstracts of 42 articles: HTML format
Single Articles
April 2025
FAN L, Shao ZM Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer.
JAMA. 2025 Apr 23. doi: 10.1001/jama.2025.1294. PubMed
PEI YY Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer.
JAMA. 2025 Apr 23. doi: 10.1001/jama.2025.1291. PubMed
March 2025
HWANG ES, Hyslop T, Lynch T, Ryser MD, et al Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma
In Situ: The COMET Randomized Clinical Trial.
JAMA. 2025;333:972-980. PubMedAbstract available
ANDERER S Trial: Less Frequent Mammograms Pose No Greater Risk After Breast Cancer.
JAMA. 2025 Mar 7. doi: 10.1001/jama.2025.1346. PubMed
LIM WH Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27807. PubMed
WESTHOFF CL, Pike MC, Pearce CL Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27795. PubMed
LUO P, Lin A, Miao K Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27804. PubMed
SLOTH MMB, Jorgensen TSH, Nybo Andersen AM Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27798. PubMed
LIBERTY AL, Rodriguez MI, Edelman A Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27810. PubMed
MORCH LS, Meaidi A, Corn G Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems-Reply.
JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27801. PubMed
January 2025
HUNTER N, Hurvitz S Where Did the Passion Go?-Rethinking Adjuvant Immune Therapy for Triple-Negative
Breast Cancer.
JAMA. 2025 Jan 30. doi: 10.1001/jama.2024.26811. PubMed
IGNATIADIS M, Bailey A, McArthur H, El-Abed S, et al Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The
ALEXANDRA/IMpassion030 Randomized Clinical Trial.
JAMA. 2025 Jan 30. doi: 10.1001/jama.2024.26886. PubMedAbstract available
December 2024
JOENSUU H Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer.
JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.25927. PubMed
CHEN L, Li H, Zhang H, Yang H, et al Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment
in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The
CamRelief Randomized Clinical Trial.
JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.23560. PubMedAbstract available
November 2024
ANDERER S ACOG Now Recommends Breast Cancer Screenings Start at Age 40.
JAMA. 2024 Nov 15. doi: 10.1001/jama.2024.23048. PubMed
ANDERER S Study: BMI May Underestimate Obesity-Linked Breast Cancer Risk.
JAMA. 2024 Nov 15. doi: 10.1001/jama.2024.23049. PubMed
ORRALL A Breast Cancer Incidence Still Rising Despite Decline in Death Rates.
JAMA. 2024 Nov 1. doi: 10.1001/jama.2024.22056. PubMed
October 2024
MORCH LS, Meaidi A, Corn G, Hargreave M, et al Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems.
JAMA. 2024 Oct 16. doi: 10.1001/jama.2024.18575. PubMed
September 2024
THORAT MA, Cuzick J, Chan AT Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15497. PubMed
PETRELLI F, Ghidini A Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15491. PubMed
LI C, He J, Liang W Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15488. PubMed
SUN R, Wei LJ Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15494. PubMed
CHEN WY, Ballman KV, Holmes MD Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer-Reply.
JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15500. PubMed
RYAN CE, Fasaye GA, Gallanis AF, Gamble LA, et al Germline CDH1 Variants and Lifetime Cancer Risk.
JAMA. 2024;332:722-729. PubMedAbstract available
August 2024
HARRIS E More Data About Risks, Benefits Might Change Breast Cancer Screening Choice.
JAMA. 2024 Aug 2. doi: 10.1001/jama.2024.13777. PubMed
July 2024
LEON-FERRE RA, Salgado R, Jonas SF Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With
Triple-Negative Breast Cancer-Reply.
JAMA. 2024 Jul 3. doi: 10.1001/jama.2024.10483. PubMed
TU H, Zhang Y, You Z Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With
Triple-Negative Breast Cancer.
JAMA. 2024 Jul 3. doi: 10.1001/jama.2024.10480. PubMed
June 2024
RUBIN R Despite New Recommendations, the Debate Over Mammography Guidelines Continues.
JAMA. 2024;331:1877-1879. PubMed
May 2024
MANSON JE, Crandall CJ, Rossouw JE, Chlebowski RT, et al The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.
JAMA. 2024;331:1748-1760. PubMedAbstract available
MANDELBLATT JS, Mainor C, Hudson BI The Aspirin Conundrum-Navigating Negative Results, Age, Aging Dynamics, and
Equity.
JAMA. 2024;331:1709-1711. PubMed
HARRIS E Young Patients Without Genetic Risk Have Low Chance of Second Breast Cancer.
JAMA. 2024 May 3. doi: 10.1001/jama.2024.6734. PubMed
April 2024
TRENTHAM-DIETZ A, Chapman CH, Jayasekera J, Lowry KP, et al Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A
Decision Analysis for the US Preventive Services Task Force.
JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.24766. PubMedAbstract available
NICHOLSON WK, Silverstein M, Wong JB, Barry MJ, et al Screening for Breast Cancer: US Preventive Services Task Force Recommendation
Statement.
JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5534. PubMedAbstract available
HENDERSON JT, Webber EM, Weyrich MS, Miller M, et al Screening for Breast Cancer: Evidence Report and Systematic Review for the US
Preventive Services Task Force.
JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.25844. PubMedAbstract available
Screening for Breast Cancer.
JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5535. PubMed
ELMORE JG, Lee CI Toward More Equitable Breast Cancer Outcomes.
JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.6052. PubMed
CHEN WY, Ballman KV, Partridge AH, Hahn OM, et al Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502
Randomized Trial.
JAMA. 2024 Apr 29:e244840. doi: 10.1001/jama.2024.4840. PubMedAbstract available
CASWELL-JIN JL, Kurian AW, Plevritis SK US Breast Cancer Mortality-Reply.
JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5482. PubMed
JATOI I US Breast Cancer Mortality.
JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5479. PubMed
NAROD SA Breast Cancer and Pregnancy in Young BRCA Carriers.
JAMA. 2024;331:1233-1234. PubMed
BLONDEAUX E, Partridge AH, Lambertini M Breast Cancer and Pregnancy in Young BRCA Carriers-Reply.
JAMA. 2024;331:1234. PubMed
LEON-FERRE RA, Jonas SF, Salgado R, Loi S, et al Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
JAMA. 2024;331:1135-1144. PubMedAbstract available